Acorn Bioventures, L.p. bought $2.6M of OKUR
owner at OnKure Therapeutics, Inc.. 1,400,000 shares at an average of $1.85, traded May 15, 2025, filed May 19, 2025.
Score components
- +12Role10% owner
- +25Trade size$2.6M at market
- +10Relative to holdingsHoldings up 97%
- +8Price context89% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-074459, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 15, 2025 | POpen-market purchase Common Stock | +270,270 | $1.85 | $500k | 1,709,944 | May 19, 2025 |
| May 15, 2025 | POpen-market purchase Common Stockindirect: By Acorn Bioventures 2, L.P. | +1,129,730 | $1.85 | $2.1M | 1,129,730 | May 19, 2025 |
Related signals
Other insiders at OnKure Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | OnKure Therapeutics, Inc. | Jason A. Leverone Chief Financial Officer | $898 302 shares | -2% | |
| 33Weak | OnKure Therapeutics, Inc. | Nicholas A Saccomano President and CEO | $259 87 shares | -1% | |
| 30Weak | OnKure Therapeutics, Inc. | Jason A. Leverone Chief Financial Officer | $896 302 shares | -2% | |
| 33Weak | OnKure Therapeutics, Inc. | Nicholas A Saccomano President and CEO | $258 87 shares | -1% | |
| 30Weak | OnKure Therapeutics, Inc. | Jason A. Leverone Chief Financial Officer | $795 303 shares | -2% | |
| 33Weak | OnKure Therapeutics, Inc. | Nicholas A Saccomano President and CEO | $231 88 shares | -2% | |
| 30Weak | OnKure Therapeutics, Inc. | Jason A. Leverone Chief Financial Officer | $722 303 shares | -2% | |
| 33Weak | OnKure Therapeutics, Inc. | Nicholas A Saccomano President and CEO | $210 88 shares | -2% | |
| 53Moderate | OKURsell OnKure Therapeutics, Inc. | Cormorant Asset Management, LP other | $3.4M 1,813,439 shares | -100% | |
| 19Weak | OKURsell OnKure Therapeutics, Inc. | Cormorant Asset Management, LP owner | $48k 24,300 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.